Education and Treatment Positioning in the Myelofibrosis Market During Q4 2025 

Novartis promoted MPN management and symptom monitoring for Jakavi through tools such as the “My MPN Symptom Tracker,” while highlighting dosing insights from the ROMEI study and individualized care approaches for myelofibrosis and polycythemia vera.

GSK positioned Omjjara through expert discussions and educational programs that addressed guideline placement, patient eligibility, treatment sequencing after ruxolitinib, and clinical outcomes such as spleen response and transfusion independence.

Bristol Myers Squibb supported healthcare professional engagement for Reblozyl through updated educational materials aligned with regulatory guidance as well as initiatives promoting doctor–patient communication and shared decision-making in oncology.